Merck KGaA (XSWX:MER) Total Long-Term Assets: CHF35,413 Mil (As of Mar. 2026)


XSWX:MER Merck KGaA XSWX:MER
82 GF Score
Price CHF132.80
GF Value CHF128.27
! 9 Warning Signs
View Full Analysis

What is Merck KGaA Total Long-Term Assets?

Merck KGaA XSWX:MER 82 Total Long-Term Assets is CHF35,413 Mil as of Mar. 2026. GuruFocus rates XSWX:MER with a GF Score™ of 82/100 and a GF Value™ of CHF128.27. The stock has 9 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Merck KGaA's Total Long-Term Assets for the quarter that ended in Mar. 2026 was CHF35,413 Mil.

Merck KGaA Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Merck KGaA's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA Total Long-Term Assets Chart

Merck KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35,778.51 35,856.73 34,046.90 35,613.59 35,736.39

Merck KGaA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35,306.75 32,974.46 35,554.46 35,736.39 35,413.03
XSWX:MER
82GF Score
Merck KGaA XSWX:MER
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck KGaA Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of CHF35,413 Mil mean?
Merck KGaA (XSWX:MER) has a Total Long-Term Assets of CHF35,413 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Merck KGaA and its competitors.
Is Merck KGaA's Total Long-Term Assets too high?
Merck KGaA's current Total Long-Term Assets is CHF35,413 Mil. Overall, Merck KGaA has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's Total Long-Term Assets compare to ZTS and UTHR?
Merck KGaA's Total Long-Term Assets of CHF35,413 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Drug Manufacturers company?
A good Total Long-Term Assets depends on the Drug Manufacturers industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Merck KGaA and its competitors. Merck KGaA's current Total Long-Term Assets is CHF35,413 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Merck KGaA (XSWX:MER) has a current Total Long-Term Assets of CHF35,413 Mil. The stock's GF Value™ is CHF128.27, compared to a current price of CHF132.80 — trading 3.5% above its estimated fair value. The current Total Long-Term Assets is CHF35,413 Mil. Merck KGaA's overall GF Score™ is 82/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Merck KGaA (XSWX:MER), the current Total Long-Term Assets is CHF35,413 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck KGaA (XSWX:MER) Overvalued in 2026?

Based on GuruFocus' analysis, Merck KGaA stock appears to be overvalued. The current stock price of CHF132.80 is trading 3.5% above its estimated GF Value™ of CHF128.27.

Key valuation signals for XSWX:MER:

  • Total Long-Term Assets: CHF35,413 Mil
  • GF Value™: CHF128.27 vs. price of CHF132.80 (3.5% above fair value)
  • GF Score™: 82/100 with 9 warning signs

No single metric tells the full story. See the XSWX:MER stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Merck KGaA Business Description

Address Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
82GF Score

Get the complete analysis for XSWX:MER

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF132.80
Price
CHF128.27
GF Value